Clinical Trial: A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for To evaluate the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective scar revision surgery by review of photographic results and Patient and Observer Scar Assessment Scales.



Original Primary Outcome: Same as current

Current Secondary Outcome: Safety evaluation of RXI-109 [ Time Frame: 9 months ]

To assess severity and frequency of reported adverse events and clinically-relevant changes in laboratory testing after elective revision of a hypertrophic scar


Original Secondary Outcome: Same as current

Information By: RXi Pharmaceuticals, Corp.

Dates:
Date Received: September 16, 2014
Date Started: July 2014
Date Completion: November 2017
Last Updated: February 6, 2017
Last Verified: May 2016